Azzad Asset Management Inc. ADV Acquires Shares of 21,077 Repligen Co. (NASDAQ:RGEN)

Azzad Asset Management Inc. ADV bought a new position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 21,077 shares of the biotechnology company's stock, valued at approximately $2,682,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Signaturefd LLC raised its holdings in Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 124 shares during the period. Sava Infond d.o.o. bought a new position in shares of Repligen during the fourth quarter worth approximately $29,000. Raiffeisen Bank International AG bought a new position in shares of Repligen during the fourth quarter worth approximately $29,000. Itau Unibanco Holding S.A. acquired a new stake in Repligen during the 4th quarter worth approximately $40,000. Finally, Global Retirement Partners LLC boosted its stake in Repligen by 54.0% in the 4th quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 129 shares during the period. Institutional investors own 97.64% of the company's stock.

Wall Street Analysts Forecast Growth

RGEN has been the subject of a number of research reports. Canaccord Genuity Group dropped their target price on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a report on Wednesday, April 16th. Evercore ISI began coverage on shares of Repligen in a research note on Tuesday, March 18th. They issued an "in-line" rating and a $155.00 price objective for the company. HC Wainwright restated a "buy" rating and set a $180.00 target price on shares of Repligen in a research report on Monday, May 5th. Wall Street Zen raised shares of Repligen from a "sell" rating to a "hold" rating in a report on Thursday, May 8th. Finally, JPMorgan Chase & Co. cut their price target on Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a research note on Tuesday, April 29th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $173.25.

Insiders Place Their Bets

In other Repligen news, Director Margaret Pax bought 250 shares of Repligen stock in a transaction on Monday, March 17th. The shares were purchased at an average cost of $150.69 per share, with a total value of $37,672.50. Following the acquisition, the director now directly owns 1,043 shares of the company's stock, valued at $157,169.67. The trade was a 31.53% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.20% of the company's stock.

Repligen Stock Performance

Repligen stock opened at $127.52 on Friday. The stock has a market cap of $7.16 billion, a PE ratio of -250.04, a P/E/G ratio of 4.54 and a beta of 1.11. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen Co. has a 12-month low of $102.97 and a 12-month high of $182.52. The business's 50-day moving average price is $128.58 and its two-hundred day moving average price is $142.91.

Repligen (NASDAQ:RGEN - Get Free Report) last released its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. The business had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm's quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.28 EPS. As a group, analysts expect that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.